AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors.
Latest Ratings for ABBV
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | UBS | Downgrades | Buy | Neutral |
| Feb 2022 | Mizuho | Maintains | Buy | |
| Feb 2022 | Barclays | Maintains | Equal-Weight |
